Group items matching

in title, tags, annotations or url

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease season. The company said in a press release that the vaccine's efficacy against RSV-associated lower respiratory tract disease with three or more symptoms was 77.8 per cent through season two, compared with efficacy of 88.9 per cent after the first RSV season, which led to the shot's US approval. The data is from a late-stage trial of more than 37,000 participants being conducted in both the Northern and Southern hemispheres. Cumulative efficacy over both seasons after around 16.4 months of disease surveillance was 81.5 per cent, Pfizer said. The data is similar to the efficacy of GSK's rival RSV shot Arexvy over two seasons, which was released in June.

The drop in vaccination rates is believed to be driving a surge in measles cases in England, mainly in the West Midlands. As of 18 January, 216 confirmed cases and 103 probable cases have been reported in the region since 1 October 2023, the UK Health Security Agency (UKHSA) revealed. The majority of cases (around 80 per cent) were from Birmingham, with children aged under 10 years being infected the most. UKHSA Chief Executive, Professor Dame Jenny Harries has warned that the outbreak could spread further to other towns and cities if urgent action is not taken to increase Measles, Mumps and Rubella (MMR) vaccination uptake in areas at greatest risk.

The Department of Health and Social Care (DHSC) has revised concession prices for four products and confirmed three further price concessions for May 2024. This announcement comes in response to representations made by Community Pharmacy England (CPE) on behalf of community pharmacy owners Concession prices have been redetermined for Ezetimibe 10mg tablets, Quetiapine 100mg tablets, Quetiapine 150mg tablets and Quetiapine 200mg tablets. Here are the newly granted concessions: Nicorandil 10mg tablets (60 tablets): £5.05 Nicorandil 20mg tablets (60 tablets): £9.30 Pregabalin 75mg capsules (56 capsules): £1.54 The revised prices will be applicable to prescriptions submitted for payment during the dispensing month of May 2024, and do not apply to June 2024 prescriptions, the CPE noted.

Amid the rapid rise in semaglutide usage, a study has suggested a potential risk of a rare eye condition associated with the weight loss drug. Semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is available under the brand name Ozempic (by Novo Nordisk) in a lower-dose form for managing type 2 diabetes mellitus (T2DM), and as Wegovy (also by Novo Nordisk) in a higher-dose form for weight management in patients with high body mass indexes. Anecdotal evidence has indicated that semaglutide might be linked to nonarteritic anterior ischemic optic neuropathy (NAION). To investigate this potential connection, researchers in the United States analysed data over a six-year period from nearly 17,000 neuro-ophthalmology patients at Massachusetts Eye and Ear Hospital in Boston, Massachusetts, all of whom had no prior history of NAION.

In response to concerns raised by pharmacy owners, the government has decided to adjust the August threshold for the Pharmacy First service from 20 to 15 clinical pathways. The ability of pharmacy owners to achieve the thresholds for the monthly Pharmacy First payments has been a topic of great concern. Community Pharmacy England (CPE) has been actively discussing this issue over the last few weeks with the Department of Health and Social Care and NHS England. Ministers have now decided to adjust the August threshold for the Pharmacy First service to 15, CPE announced today (July 31). Commenting on this decision, Janet Morrison, CEO of Community Pharmacy England said: "We are pleased that Ministers have listened to our concerns and acted quickly to make an adjustment so soon after coming into office."

In his first speech as Secretary of State for Health and Social Care, Wes Streeting MP acknowledged that the NHS is in crisis while outlining his mission to save the health service. Streeting described the current state of the NHS as "broken," noting its failure to meet the needs of both patients and dedicated healthcare professionals. "When we said during the election campaign, that the NHS was going through the biggest crisis in its history, we meant it. "When we said that patients are being failed on a daily basis, it wasn't political rhetoric, but the daily reality faced by millions," he said on Friday (5 July). The new health secretary remarked that previous governments had been unwilling to admit these simple facts.

New amendments to the Human Medicines Regulations will soon allow registered pharmacy technicians to supply and administer medicines under Patient Group Directions (PGDs). Laid before Parliament at the end of May, the legislative changes will come into effect from June 26, 2024, the Community Pharmacy England (CPE) announced today. The introduction of this new legislation follows an announcement made by the Department of Health and Social Care (DHSC) earlier this year. The regulatory adjustments provide the legal framework for pharmacy technicians to engage in the supply and administration of medicines under PGDs in the course of their professional practice. However, there will be no immediate change in the provision of community pharmacy services, the CPE noted